Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

Right now, approximately 20 billion red blood cells are busy traveling through your blood vessels. They are delivering oxygen ...

The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

A cutting-edge gene therapy has been approved for NHS use for some patients with severe sickle cell disease. Casgevy, also ...

CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel).

CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...